共 9 条
[1]
Administration route dependency of absorption of glycyrrhizin in rat_s: intraperitoneal administration dramatically enhanced bioavailabilit y. Yamamura Y,Santa T,Kotaki H,et al. Biological and Pharmaceutical Bulletin . 1995
[2]
Intraveno_us glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo controlled pha_se I/II trial. Van Rossum TG,Vulto AG,Hop WC,et al. Journal of Gastroenterology . 1999
[3]
Bioavailabilit y study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. Takeda S,Ishthara K,Wakui Y,et al. Journal of Pharmacokinetics and Pharmacodynamics . 1996
[4]
Review article: glycyrrhizin as a potential treatment for chron_ic hepatitis C. Van Rossum TG,Vulto AG,De Man RA,et al. Alimentary Pharmacology and Therapeutics . 1998
[5]
Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. Okamoto T,Kanda T,Vulto AG,et al. Int J Mol M_ecl . 1999
[6]
Corrbinecl ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Tsabota A. Eur J Gastroenterd Hepatol . 1999
[7]
The protective effect of glycyrrhizin on anti-fas antibody-induced hepatitis in mice. Okamoto T,Tanaka N,Vulto AG,et al. European Journal of Pharmacology . 2000
[8]
Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosa_mine-treated mice. Shiota G,Harada K,Ishida M,et al. Carcinogenesis . 1999
[9]
The pharmaco_kinetics of glycyrrhizin and its restorative effect on he_patic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats. Yamamura Y,Kotaki H,Tanaka N,et al. Biopharmaceutics and Drug Disposition . 1997